Navigation Links
ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
Date:5/29/2009

EXTON, Pa., May 29 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) announced today that it will convene a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to discuss bioequivalence recommendations for oral vancomycin hydrochloride capsule drug products. The meeting is scheduled for August 4, 2009. FDA will make background material available to the public no later than two days before the meeting at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.

Vancocin is the only approved product to treat Clostridium difficile-associated pseudomembranous colitis, one of the most common and devastating hospital-acquired infections. Clostridium difficile infection (CDI) can be severe, and without proper treatment, the associated complications of the disease can be deadly. The incidence of the disease observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million.

"ViroPharma views the convening of the advisory committee as a positive step towards open dialogue to discuss this very serious public health issue," commented Thomas Doyle, ViroPharma's vice-president, strategic initiatives. "ViroPharma will have an opportunity to address the Committee, and we look forward to what we hope will be a robust discussion of the many important issues raised by the Office of Generic Drugs' in vitro approach to bioequivalence for Vancocin."

About Clostridium difficile

One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs). Clostridium difficile infection is one of the most common and devastating HAIs. The incidence of C. difficile observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million. Elderly patients exposed to antibiotics, long-term care patients, or those that have a serious underlying illness, are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea, fever, nausea and abdominal pain and dehydration, though cases can lead to life threatening complications such as megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties including the Company's expectation that it will have an opportunity to address the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology and the expectation that a robust discussion of the OGD's in vitro approach to bioequivalence for Vancocin will occur. There can be no assurance that the FDA will continue with its stated plans regarding the subject matter of the Advisory Committee meeting, that the FDA will agree with the positions stated in ViroPharma's Vancocin related submissions or that ViroPharma's efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either ViroPharma's citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the FDA's December 2008 bioequivalence guidance for Vancocin, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2009 could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at Two May Healthcare Conferences
2. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
3. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
4. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
5. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
6. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. ViroPharma Provides Update on Vancocin(R)
8. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
9. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
10. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
11. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... Pets bring laughter, ... token of appreciation, pet owners celebrate National Pet Week, which falls on the first ... remind pet owners to cherish the human-animal bond and recognize responsible pet ownership. Pet ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight Behavioral Health Center ... disorders, has rebranded its eating disorder program under a new name: Eating Recovery Center, ... on May 16. , To celebrate, ERC Chicago will host a ribbon-cutting ceremony ...
(Date:5/2/2016)... ... , ... In honor of National Physical Fitness and Sports Month in May, ... fitness journey on social media. , The foot care company, which specializes in ... voucher each week during May to one winner. , “Whether the goal is to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, dentist in ... day treatments. In the past, many necessary dental treatments could require multiple appointments to ... anesthetic shots and extra chair time. Not only could this be inconvenient, but it ...
(Date:5/2/2016)... ... 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is proud to announce ... its mail back service for an all-inclusive rate. MedPro Disposal President, Dan Hansen, says, ... to all of the clients in the country who are looking for an alternative ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... 2016  The blood testing market in ... Kalorama Information and The Freedonia Group in a recent ... testing.  The healthcare research firm said that ... collection stations and in improving testing at the provincial ... Blood Testing Market in China , ...
(Date:4/28/2016)... -- , Net Sales of $1.90 billion represent an ... year period, and an increase of 1.2% on an adjusted ... the first quarter were $0.52 reported, a decrease of 47.5% ... of 29.9% over the prior year period , The ... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
Breaking Medicine Technology: